A 5-year (1990-1994) neuroblastoma screening feasibility study in France. Methodology and preliminary observations

Early Human Development

Volumn 46, Issue 1-2, 1996, Pages 177-196

  Mathieu, P ^a   Frappaz, D ^a,b   Chauvin, F ^a,b   Combaret, V ^a,b   Vercherat, M ^a,c   Brunat Mentigny, M ^a,b   David, L ^a,d   Esteve, J ^a,e   Favrot, M ^a,b   Fouillat, V ^a   Greffe, J ^a   Lasset, C ^a,b   Renaud, P ^a,d   Philip, T ^a,b  

^a CENTRE HOSPITALIER LE VINATIER   (France)

^b CENTRE LÉON BÉRARD   (France)

^c HÔTEL DIEU   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

High performance liquid chromatography (HPLC); Homovanillic acid (HVA); Neuroblastoma; Screening; Tumour markers; Vanillylmandelic acid (VMA)

Indexed keywords

CREATININE; HOMOVANILLIC ACID; TUMOR MARKER; VANILMANDELIC ACID;

ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEASIBILITY STUDY; FRANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MASS SCREENING; MORTALITY; NEUROBLASTOMA; NEWBORN; URINALYSIS;

EID: 0030595354     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-3782(96)01763-X     Document Type: Article

References (44)

1. [1] Tuchman, M., Aurais-Blais, C., Ramnaraine, M.L., Neglia, J., Krivit, W. and Lemieux, B. (1987): Determination of urinary homovanillic and vanillylmandelic acids from dried paper samples: assessment of potential methods for neuroblastoma screening. Clin. Biochem., 20, 173.
2. [2] Sawada, T., Kidowaki, T., Sakamoto, I., Hashida, T., Matsumura, T., Nakagawa, M. and Kusunoki, T. (1984): Neuroblastoma. Mass screening for early detection and its prognosis. Cancer, 53, 2731.
3. [3] Takeda, T., Hatae, Y., Nakadate, H., Nishi, M., Hanai, V., Sato,Y. and Takasugi, N. (1989): Japanese experience of screening. Med. Ped. Oncol., 17, 368.
4. [4] Tuchman, M., Fisher, E.J., Heisel, M.A. and Woods, W.G. (1989): Feasibility study for neonatal neuroblastoma screening in the United States. Med. Ped. Oncol., 17, 258.
5. [5] Schilling, F., Treuner, J. and Erttmann, R. (1991): Neuroblastoma screening in Germany: methods of the pilot study. In: Neuroblastoma screening, p. 13. Editors: W.G. Woods and M. Tuchman. IInd Intern Symp. Minneapolis: Cont med educ., Med School.
6. [6] Craft, A.W., Parker, L., Dale, G., Mc Gill, A., Seviour, J.A., Bell, S., Cole, M. and Smith, J. (1992): A pilot study of screening for neuroblastoma in the north of England. Am. J. Pediatr. Hematol./Oncol., 14, 337.
7. [7] Sawada, T. (1992): Past and future of neuroblastoma screening in Japan. Ann. J. Pediatr. Hematol./Oncol., 14, 320.
8. [8] Mathieu, P., Favrot, M., Frappaz, D., Chauvin, F., Greffe, J., Montegue, A., Lacroix, C., David. L., Brunat-Mentigny, M. and Philip, T. (1993): Le neuroblastome de l'enfant: aspects cliniques et biologiques. Une expérience de dépistage en France. Ann. Biol. Clin., 51, 665.
9. [9] Schilling, F.H., Erttmann, R., Dohrmann, S., Nieber, B., Erb, N., Gross-Wieltsch, U. and Treuner, U. (1994): Two years experience of the German pilot study for the early detection of neuroblastoma. In: New trends in neonatal screening, p. 165. Editors: N. Takasugi and H. Naruse. Hokkaido Univ Press.
10. [10] La Brosse, E.H. (1968): Biochemical diagnosis of neuroblastoma. Use of a urine spot-test. Proc. Am. Assoc. Cancer Res., 9, 39.
11. [11] Takeda, T. (1989): History and current status of neuroblastoma screening in Japan. Med. Ped. Oncol., 17, 361.
12. [12] Aurais-blais, Ch., Giguere, R. and Lemieux, B. (1989): Thin-layer chromatography of urinary homovanillic acid and vanillylmandelic acid for large-scale neuroblastoma mass screening. Med. Ped. Oncol., 17, 364.
13. [13] Lemieux, B., Aurais-Blais, C., Giguere, R., Shapcott, D. and Scriver, C.R. (1988): Newborn urine screening experience with over one million infants in the Quebec network of genetic medicine. J. Inner. Metabol. Dis., 11, 45.
14. [14] Lemieux, B. (1991): Methods of screening in the Quebec project In: Neuroblastoma screening, p. 9. Editors: W.G. Woods and M. Tuchman., IInd Intern Symp. Minneapolis: Cont med educ., Med School.
15. [15] Tuchman, M., Ramnaraine, H.L., Woods, W.G. and Krivit, W. (1987): Three years experience with random urinary HVA and VMA levels in the diagnosis of neuroblastoma. Pediatrics, 78, 203.
16. [16] Craft, A.W., Dale, G., Mc Gill, A. and Seviour J. (1989): Biochemical screening for neuroblastoma in infants: a feasibility study. Med. Ped. Oncol., 17, 373.
17. [17] Craft, A.W. (1991): Screening in Northern England In: 'Neuroblastoma screening, IInd Intern Symp' Continuing. Med Educ, Med School, Minneapolis, p. 31.
18. [18] Sato, Y., Hanai, J., Takasugi, N. and Takeda, T. (1986): Determination of urinary vanillylmandelic acid and homovanillic acid by high performance liquid chromatography for mass screening of neuroblastoma. Tohoku J. Exp. Med., 150, 169.
19. [19] Hanai, J., Kawai, T., Sato, Y., Takasugi, N., Nishi, M. and Takeda, T. (1987): Simple liquid chromatographic measurement of vanillylmandelic acid in urine on filter paper for mass screening of neuroblastoma in infants. Clin. Chem., 33, 2043.
20. [20] Kuroda, M., Sugi, M., Ikeda, T., Fujimoto, M., Yokomori, K. and Yoshioka, M. (1990): Enzyme immunoassay of vanylmandelic acid in urine. Biogenic Amines, 7, 257.
21. [21] Yokomori, K., Hori, T., Tsuchida, Z., Kuroda, M. and Yoshioka, M. (1989): A new urinary mass screening system for neuroblastoma in infancy by use of monoclonal antibody against VMA and HVA. J. Pediatr. Surg., 24, 391.
22. [22] Watanabe, N., Naruse, H., Umehashi, T., Tazaki, R., Hanai, J., Fukushi, M. and Sawada, T. (1993): Comparison of HPLC and ELISA methods in neuroblastoma screening. Screening, 2, 33.
23. [23] Kerbl, R., Urban, C., Starz, I., Ambros, I.M., Strehl, S., Kovar, H., Gadner, H. and Ambros, P.F. (1993): Neuroblastoma with Nmyc amplification detected by urine mass screening of infants after the 6th month of life. Med. Ped. Oncol., 21, 625.
24. [24] Evans, A.E., D'Angio, G.J. and Randolph, J. (1971): A proposed staging for children with neuroblastoma. Cancer, 27, 374.
25. [25] Mathieu, P., Philip, T., Greffe, J., Montegue, A. and Lacroix, C. (1993): A simple coloured paper-thin layer chromatography test as a backup procedure for vanillylmandelic acid and homovanillic acid evaluation in a neuroblastoma screening program. Clin. Chim. Acta, 220, 229.
26. [26] Renaux, P., Mathieu, P., Chauvin, F., Collet, J.P., Greffe, J., Lacroix, C., Narod, S., Vocanson, M., Ducos-Mieral, C., Boschetti, R., David, L. and Philip, T.O. (1990): Le neuroblastome dans la région Rhône-Alpes: données épidémiologiques. Pédiatrie, 45, 59.
27. [27] Gembara, P., Dechelotte, P., Chazal, J., Chauvin, F., Chopard, P., Goddon, R., Goumy, P., Masson, A., Malpuech, G. and Demeocq, F. (1993): Le neuroblastome dans la région Auvergne de 1986 à 1991: données épidémiologiques. Pédiatrie, 48, 801.
28. [28] Tuchman, M., Fisher, E., Heisel, M. and Wood, W.G. (1989): Feasibility study for neonatal neuroblastoma screening in the United States. Med. Ped. Oncol., 17, 258.
29. [29] Sawada, T., Kawakatsu, H., Matsumura, T., Kizaki, Z., Shikata, T. and Sugimoto, T. (1993): Recent results of neuroblastoma mass screening in Japan In: Neuroblastoma screening, p. 101. Editors: T. Sawada, T. Matsumura and Z. Kizaki. 3rd intern symp. Kyoto: Prefect univ med., Dept ped.
30. [30] Craft, A.W. (1993): Neuroblastoma screening: lessons from the North of England In: Neuroblastoma screening, p. 4. Editors: T. Sawada, T. Matsumura and Z. Kizaki. 3rd intern symp. Kyoto: Prefect univ med., Dept ped.
31. [31] Nishi, M., Miyake, H., Takeda, T., Yonemori, H., Hanai, J., Kikuchi, Y. and Takasuchi, N. (1995): Cases of spontaneous regression and true patients detected in mass screening for neuroblastoma. Intern. J. Ped. Hematol. Oncol., 1, 557.
32. [32] Berthold, F., Hunneman, D.J. and Sander, J. (1991): Basic clinical points for neuroblastoma screening. In: Neuroblastoma screening, p. 6. Editors: W.G. Woods and M. Tuchman. IInd Intern Symp. Minneapolis: Cont med educ., Med School.
33. [33] Nishi, M., Miyake, H., Takeda, T., Hanai, J., Yonemori, H. and Takasugi, N. (1992): Mass screening of neuroblastoma in Sapporo City, Japan. Amer. J. Pediatr. Hematol./Oncol., 14, 327.
34. [34] Nishi, M., Niyake, H., Takeda, T., Yonemori, H., Hanai, J., Kikuchi, Y. and Takasugi, N. (1993): Mass screening and occurence of neuroblastoma in Sapporo City. Screening, 2, 99.
35. [35] Lauge, W.E., Siegel, S.E., Shaw, K.N.F., Landing, B., Baptista, J. and Gutenstein, M. (1978): Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics, 62, 77.
36. [36] Hartmann, O. and Favrot, M.C. (1993): Neuroblastomes. Aspects cliniques et thérapeutiques actuels. Apports de la biologie moderne. Rev. Prat., 43, 2182.
37. [37] Kodama, K., Tsuchiya, H., Kojima, A., Ishii, J., Yamanaka, K. and Horibe, K. (1993): Recent results of mass screening for neuroblastoma in Nagoya City, Japan. In: Neuroblastoma screening, p. 16. Editors: T. Sawada, T. Matsumura and Z. Kizaki. 3rd intern symp. Kyoto: Prefect univ med., Dept ped.
38. [38] Tanaka, T., Tanabe, M., Sugimoto, T. and Sawada, T. (1993): Evaluation of age-related heterogeneity in neuroblastoma. In: Neuroblastoma screening, p. 20. Editors: T. Sawada, T. Matsumura and Z. Kizaki. 3rd intern symp. Kyoto: Prefect univ med., Dept ped.
39. [39] Takeda, T., Shimada, M., Nakadate, H., Nishi, M., Hanai, J., Yonemori, H., Kikuchi, Y. and Takasuchi, N. (1993): Mass screening for neuroblastoma of 6-months infants using HPLC method: report from Sapporo City. In: Neuroblastoma screening, p. 5. Editors: T. Sawada, T. Matsumura and Z. Kizaki. 3rd intern symp. Kyoto: Prefect univ med., Dept ped.
40. [40] Bell, S., Parker, L., Craft, A.W., Dale, G., Mc Gill, A., Seviour, J., Cole, M. and Smith, J. (1994): False positive results in a neuroblastoma screening programme. Med. Ped. Oncol., 22, 181.
41. [41] Murphy, S.B., Cohn, S.L., Craft, A.W., Woods, W.G., Sawada, T., Castelberry, R.P., Levy, H.L., Prock, P.C. and Denman-Hammon, G. (1991): Do children benefit from mass screening for neuroblastoma? Consensus statement from the American Cancer Society workshop on neuroblastoma screening. Lancet, 337, 344.
42. [42] Sankila, R. and Hakama, M. (1992): Survival trends for neuroblastoma patients in Finland: negative reflexion on screening. Eur. J. Cancer, 29A, 122.
43. [43] Huddart, S.N., Muir, K.R., Parkes, S., Mann, J.R., Stevens, M.C.G. and Raafat, F. (1993): Neuroblastoma: a 32-year population-based study. Implications for screening. Med. Ped. Oncol., 21, 96.
44. [44] Lemieux, B., Woods, W., Campion, P., Leclerc, J.M., Bernstein, M.L., Brisson, L., Brossard, J., Weitzmal, S., Giguer, R. and Tuchman, M. (1994): Neuroblastoma screening: the North American experience In: New Horizons in Neonatal Screening, p. 231. Editors: J.P. Farriaux and L. Dhont. Amsterdam: Elsevier/North Holland.